当前位置: X-MOL 学术Mol. Carcinog. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Novel MLL/KMT2A-MON2 fusion in a child with therapy-related acute myeloid leukemia after treatment for acute promyelocytic leukemia
Molecular Carcinogenesis ( IF 4.6 ) Pub Date : 2021-07-08 , DOI: 10.1002/mc.23333
Yanlei Gong 1, 2 , Man Wang 1 , Hongjie Shen 1 , Yan Chen 1 , Jiannong Cen 1 , Xiaolin Yin 3 , Li Yao 1, 2
Affiliation  

Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML), which is characterized by the reciprocal t (15;17) (q24; q21) translocation, resulting in PML–RARA gene fusion. Therapy-related AML (t-AML) is a serious complication after cytotoxic and/or radiation therapy in many malignant diseases. In this report, MLL/KMT2A-MON2, with balanced chromosomal translocation t (11;12) (q23; q14), was identified as a novel fusion in a child transformed to t-AML after successful treatment of APL. This study emphasized that clinical monitoring with an integrated laboratory approach is essential for the diagnosis and treatment of t-AML.

中文翻译:

急性早幼粒细胞白血病治疗后与治疗相关的急性髓系白血病儿童的新型 MLL/KMT2A-MON2 融合

急性早幼粒细胞白血病 (APL) 是急性髓系白血病 (AML) 的一个独特亚型,其特征是相互 t (15;17) (q24; q21) 易位,导致 PML-RARA 基因融合。治疗相关的 AML (t-AML) 是许多恶性疾病细胞毒性和/或放射治疗后的严重并发症。在本报告中,具有平衡染色体易位 t (11;12) (q23; q14) 的 MLL/KMT2A-MON2 被鉴定为成功治疗 APL 后转化为 t-AML 的儿童的新型融合。本研究强调,采用综合实验室方法进行临床监测对于 t-AML 的诊断和治疗至关重要。
更新日期:2021-07-08
down
wechat
bug